733DOI: 10.17235/reed.2018.5598/2018
Letter
Intestinal ultrasound and its role in the acute setting: stenosing Crohn’s disease and acute bowel obstruction due to foreign body ingestion (dental post and crown)
DOI: 10.17235/reed.2024.10677/2024
Pancreatic duct occupation method assisted wire guide through pancreatic duct stenosis in the treatment of chronic pancreatitis
DOI: 10.17235/reed.2024.10586/2024
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) complicated with intestinal obstruction and perforation
DOI: 10.17235/reed.2024.10407/2024
Removal of an impacted apricot pit from a scarring duodenal stenosis using the endoscopic retrograde cholangiopancreatography (ERCP) stone extraction technique
DOI: 10.17235/reed.2023.10019/2023
Comments on: “Perianal Crohn’s disease: clinical implications, prognosis and use of resources”
DOI: 10.17235/reed.2023.10013/2023
Intestinal stenosis developed after a complete response to chemotherapy in a patient with Crohn’s disease and lymphoma of the jejunum
DOI: 10.17235/reed.2023.10004/2023
Coincidental oral lesions in Crohn’s disease
DOI: 10.17235/reed.2023.9992/2023
Transient second-degree type 2 atrioventricular block after infliximab infusion in a patient with Crohn’s disease and heterozygous familial hypercholesterolemia
DOI: 10.17235/reed.2023.9950/2023
Original
Psychological disorders and coping strategies in patients with inflammatory bowel disease. Their impact on health-related quality of life
DOI: 10.17235/reed.2023.9935/2023
Pseudoachalasia as a paraneoplastic event in a patient with Hodgkin’s disease
DOI: 10.17235/reed.2023.9921/2023
Gastric peroral endoscopic pyloromyotomy for the treatment of a congenital hypertrophic pyloric stricture in an infant with a self-made bite block
DOI: 10.17235/reed.2023.9875/2023
Is cervical dysplasia a major concern in females with inflammatory bowel disease? A Spanish retrospective study
DOI: 10.17235/reed.2023.9890/2023
FiLaC® procedure for highly selected anal fistula patients: indications, safety and efficacy from an observational study at a tertiary referral center
DOI: 10.17235/reed.2023.9644/2023
Efficacy and safety of intravenous ustekinumab maintenance therapy in Crohn’s disease.
DOI: 10.17235/reed.2023.9594/2023
Intestinal obstruction secondary to Brunner’s glands hyperplasia
DOI: 10.17235/reed.2023.9538/2023
Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis
DOI: 10.17235/reed.2023.9537/2023
A rare case of an esophageal neuroendocrine carcinoma arising on an endoscopic resection scar
DOI: 10.17235/reed.2023.9523/2023
Duodenal stenosis surgical treatment in Crohn’s disease
DOI: 10.17235/reed.2023.9521/2023
Editorial
Transmural or mucosal healing in Crohn´s disease. Which is the goal to be pursued?
DOI: 10.17235/reed.2023.9492/2023
Digestive Diseases Image
Endoscopic submucosal dissection using an ultrathin endoscope for esophageal squamous cell carcinoma with anastomotic stenosis
DOI: 10.17235/reed.2023.9461/2023
Isolated Jejunal Crohn's Disease: a challenging diagnosis
DOI: 10.17235/reed.2022.9423/2022
Henoch-Schönlein purpura masquerading as Crohn’s disease flare
DOI: 10.17235/reed.2022.9414/2022
Effectiveness and safety of ustekinumab dose escalation in Crohn’s disease: a multicenter observational study
DOI: 10.17235/reed.2023.9402/2022
Use of teduglutide for short bowel syndrome and Crohn’s disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy
DOI: 10.17235/reed.2022.9194/2022
Challenge scenario: mid-gastric stenosis and gastric tube twist following laparoscopic sleeve gastrectomy
DOI: 10.17235/reed.2022.9185/2022
Successful treatment of Crohn’s disease, aseptic liver abscess and psoriasis with ustekinumab
DOI: 10.17235/reed.2022.9155/2022
Comb sign in Crohn’s disease
DOI: 10.17235/reed.2022.9132/2022
Varicella zoster virus encephalitis: a potentially serious complication during treatment with vedolizumab
DOI: 10.17235/reed.2022.9121/2022
Gastric ischemia secondary to intestinal occlusion due to gallstone ileus
DOI: 10.17235/reed.2022.9083/2022
An atypical gastric duplication cyst as a rare cause of gastric dilatation: the key role of the endoscopy ultrasound
DOI: 10.17235/reed.2022.9024/2022
Review
“Out of the box” new therapeutic strategies for Crohn´s disease: moving beyond biologics
DOI: 10.17235/reed.2022.9010/2022
A diagnostic challenge: chronic cutaneous ulcers as an isolated clinical finding in metastatic Crohn’s disease
DOI: 10.17235/reed.2022.8995/2022
Intestinal and perianal tuberculosis: an uncommon clinical presentation and challenging diagnosis
DOI: 10.17235/reed.2022.8988/2022
Endoscopic radial incision to treat a congenital esophageal stenosis in a 10-year-old child
DOI: 10.17235/reed.2022.8931/2022
Peristomal cutaneous Crohn's disease by contiguity
DOI: 10.17235/reed.2022.8909/2022
Predictive value of patency capsule and magnetic resonance enterography for capsule endoscopy retention in patients with established Crohn’s disease
DOI: 10.17235/reed.2022.8848/2022
Ectopic ACTH syndrome in a patient with Crohn’s disease
DOI: 10.17235/reed.2022.8825/2022
Intestinal disease secondary to tocilizumab
DOI: 10.17235/reed.2022.8818/2022
Esophageal stricture as an initial manifestation of Crohn's disease
DOI: 10.17235/reed.2022.8766/2022
Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak
DOI: 10.17235/reed.2022.8668/2022
Pulmonary nodules in a patient with Crohn’s disease
DOI: 10.17235/reed.2022.8499/2021
Experience with ustekinumab in reservoir Crohn's disease
DOI: 10.17235/reed.2021.8457/2021
Crack cocaine abuse as an undescribed cause of gastric outlet obstruction
DOI: 10.17235/reed.2022.8438/2021
Managing esophageal strictures following endoscopic resection of superficial neoplastic lesions
DOI: 10.17235/reed.2021.8437/2021
Anal neoplasia and perianal Crohn’s disease: myth or reality?
DOI: 10.17235/reed.2021.8317/2021
A new single-use disposable duodenoscope (EXALT™ Model D) for the treatment of an anastomotic biliary stenosis in a liver transplant patient
DOI: 10.17235/reed.2021.8201/2021
Ileal endometriosis in a patient with Crohn’s disease: a diagnostic challenge
DOI: 10.17235/reed.2021.8187/2021
Risk factors of refractory post-endoscopic submucosal dissection esophageal strictures
DOI: 10.17235/reed.2021.8061/2021
Adenocarcinoma of the small intestine in Crohn's disease
DOI: 10.17235/reed.2021.8050/2021
Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area
DOI: 10.17235/reed.2021.8003/2021
Perianal Crohn’s disease: clinical implications, prognosis and use of resources
DOI: 10.17235/reed.2021.7918/2021
Role of contrast-enhanced ultrasonography in the management of chronic inflammatory bowel disease
DOI: 10.17235/reed.2021.7780/2020
Usefulness of peripheral blood monocyte count to predict relapse in patients with inflammatory bowel disease: a prospective longitudinal cohort study
DOI: 10.17235/reed.2021.7683/2020
Endoscopic retrograde cholangiopancreatography and carbohydrate antigen 19-9 in the differential diagnosis of biliary strictures
DOI: 10.17235/reed.2021.7711/2020
The use of contrast-enhanced ultrasound for chronic inflammatory bowel disease
DOI: 10.17235/reed.2020.7499/2020
Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results
DOI: 10.17235/reed.2020.7472/2020
Intestinal obstruction secondary to Crohn-like disease in common variable immu-nodeficiency
DOI: 10.17235/reed.2020.7440/2020
Prognostic value of ultrasound activity and parietal healing in patients with Crohn’s disease
DOI: 10.17235/reed.2020.7347/2020
Ustekinumab in Crohn's disease: real-world outcomes and predictors of response
DOI: 10.17235/reed.2020.7352/2020
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease
DOI: 10.17235/reed.2020.7232/2020
Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses
DOI: 10.17235/reed.2020.7230/2020
Ustekinumab treatment for toxic megacolon in severe colonic Crohn’s disease
DOI: 10.17235/reed.2020.7228/2020
Prevalence and factors associated with poor sleep quality in inflammatory bowel disease outpatients
DOI: 10.17235/reed.2020.7202/2020
The role of endoscopy in caustic ingestion in the pediatric population: experience in a tertiary center
DOI: 10.17235/reed.2020.7171/2020
Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn’s disease. A real life study
DOI: 10.17235/reed.2020.7124/2020
Vitamin D and inflammatory bowel disease: what do we know so far?
DOI: 10.17235/reed.2020.7061/2020
The diagnostic and predictive value of fecal calprotectin and capsule endoscopy for small-bowel Crohn’s disease: a systematic review and meta-analysis
DOI: 10.17235/reed.2020.6996/2020
Normalization of long-term quality of life in Crohn’s disease patients receiving ustekinumab
DOI: 10.17235/reed.2020.6941/2020
Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases
DOI: 10.17235/reed.2020.6938/2020
Retrograde enteroclysis by double balloon enteroscopy in a patient with blunt abdominal trauma: small bowel stricture, intraluminal vascular lesion and Crohn’s disease
DOI: 10.17235/reed.2020.6891/2020
Treatment of abdominal fistulas in Crohn’s disease and monitoring with abdominal ultrasonography
DOI: 10.17235/reed.2020.6884/2020
Is endoscopic treatment of small bowel strictures effective and safe in patients with Crohn’s disease?
DOI: 10.17235/reed.2020.6852/2019
Meta-analysis of protein intake on the effect of Crohn’s disease and ulcerative colitis
DOI: 10.17235/reed.2020.6851/2019
Comparison of original and biosimilar infliximab (CTP-13) in biologic-naïve patients with Crohn’s disease and ulcerative colitis: a retrospective, multicenter real-life study in Spain
DOI: 10.17235/reed.2020.6847/2019
Transverse myelitis associated with Crohn's disease: an exceptional case, idiopathic or secondary?
DOI: 10.17235/reed.2020.6920/2019
Vedolizumab-associated psoriasis: until where does gut selectivity go?
DOI: 10.17235/reed.2020.6817/2019
Is the degree of i2a recurrence in Crohn’s disease secondary to ischemic phenomena?
DOI: 10.17235/reed.2020.6790/2019
Groove pancreatitis: a rare cause of severe gastric dilation
DOI: 10.17235/reed.2020.6765/2019
Intra-abdominal desmoid tumor and chronic inflammatory bowel disease. An uncommon scenario
DOI: 10.17235/reed.2020.6648/2019
Esophageal perforation after dilation due to a peptic stricture that concealed esophageal cancer
DOI: 10.17235/reed.2020.6624/2019
Crohn’s disease in patients treated with etanercept
DOI: 10.17235/reed.2019.6554/2019
Diet as an environmental trigger in inflammatory bowel disease: a retrospective comparative study in two European cohorts
DOI: 10.17235/reed.2020.6552/2019
Laparoscopic treatment of acute abdomen due to a massive gastric dilatation
DOI: 10.17235/reed.2019.6535/2019
Lewis score: a useful tool for diagnosis and prognosis in Crohn’s disease
DOI: 10.17235/reed.2020.6434/2019
Twisting of sleeve gastrectomy: two ways of clinic presentation
DOI: 10.17235/reed.2019.6366/2019
Inflammatory bowel disease – Newer models of care
DOI: 10.17235/reed.2019.6495/2019
Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease
DOI: 10.17235/reed.2019.6298/2019
Endoscopic retrograde cholangiopancreatography in the management of biliary complications after orthotopic liver transplantation
DOI: 10.17235/reed.2019.6284/2019
Case Report
Regression of a giant pseudopolyp in a patient with colonic Crohn’s disease after therapy with infliximab
DOI: 10.17235/reed.2019.6252/2019
Endoscopic balloon dilation in duodenal stenosis secondary to intestinal lymphoma in a heart transplant patient
DOI: 10.17235/reed.2019.6221/2019
Incisional endoscopic therapy as a therapeutic alternative in esophageal anastomotic strictures refractory to conventional treatment
DOI: 10.17235/reed.2019.6196/2019
Differences in the need for adalimumab dose optimization between Crohn’s disease and ulcerative colitis
DOI: 10.17235/reed.2019.6148/2018
A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn’s disease
DOI: 10.17235/reed.2019.5990/2018
Aganglionic megacolon in the adult. Urgent and surprising cause of intestinal occlusion
DOI: 10.17235/reed.2019.5922/2018
Endoscopic papillary large balloon dilatation for the extraction of common bile duct stones
DOI: 10.17235/reed.2019.5865/2018
Intravenous ustekinumab reinduction as a Crohn’s disease rescue strategy following a secondary non-response
DOI: 10.17235/reed.2019.5802/2018
Crohn’s disease and cystic fibrosis: there is still a lot to learn
DOI: 10.17235/reed.2018.5725/2018
Intraductal ablation by radiofrequency for inoperable biliopancreatic neoplasms with jaundice: experience at a regional hospital
DOI: 10.17235/reed.2019.5720/2018
Vitamin D deficiency in outpatients with inflammatory bowel disease: prevalence and association with clinical-biological activity
DOI: 10.17235/reed.2018.5714/2018
Apparent diffusion coefficient and enhancement patterns in MR imaging as markers of severe or moderate ileum inflammation in Crohn’s disease
DOI: 10.17235/reed.2018.5691/2018
Complete resolution of dysphagia after sequential Polyflex™ stenting in a case of recurrent anastomotic stenosis in an adult with congenital esophageal atresia
DOI: 10.17235/reed.2018.5620/2018
Todani Ic cystic dilatation of the bile duct
DOI: 10.17235/reed.2018.5609/2018
Sweet syndrome after treatment with vedolizumab in a patient with Crohn’s disease
DOI: 10.17235/reed.2018.5603/2018
The association between de novo inflammatory bowel disease and celiac disease
DOI: 10.17235/reed.2019.5535/2018
Online social networks and inflammatory bowel disease
DOI: 10.17235/reed.2018.5496/2018
Bile acid malabsorption in patients with chronic diarrhea and Crohn’s disease
DOI: 10.17235/reed.2018.5376/2017
Factors associated with complications during endoscopic esophageal dilation
DOI: 10.17235/reed.2018.5375/2017
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
DOI: 10.17235/reed.2018.5368/2017
Letter to the Editor
Complicated peribiliary cysts in patient without any prior liver disease
DOI: 10.17235/reed.2017.5350/2017
Using the internet to evaluate the opinion of patients with inflammatory bowel disease with regard to the available information
DOI: 10.17235/reed.2018.5331/2017
Intestinal tuberculosis and Crohn’s disease: the importance and difficulty of a differential diagnosis
DOI: 10.17235/reed.2018.5184/2017
Can we rely on inflammatory biomarkers for the diagnosis and monitoring Crohn’s disease activity?
DOI: 10.17235/reed.2017.5126/2017
Enteral nutrition is associated with a decreased risk of surgical intervention in Crohn’s disease patients with spontaneous intra-abdominal abscess
DOI: 10.17235/reed.2017.5116/2017
Acute gastric dilatation after dietary violation
DOI: 10.17235/reed.2017.5111/2017
Capsule endoscopy with PillCamSB2 versus PillCamSB3: has the improvement in technology resulted in a step forward?
DOI: 10.17235/reed.2017.5071/2017
Serrated polyposis syndrome associated with long-standing inflammatory bowel disease
DOI: 10.17235/reed.2017.5068/2017
Hypersensitivity to azathioprine in a patient with Crohn’s disease: a case report
DOI: 10.17235/reed.2017.5031/2017
EUS-guided recanalization of complete gastrointestinal strictures
DOI: 10.17235/reed.2017.4972/2017
Use of self-expanding nitinol stents in the pediatric management of refractory esophageal caustic stenosis
DOI: 10.17235/reed.2017.4959/2017
Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn’s disease
DOI: 10.17235/reed.2017.4931/2017
Rectal inflammatory stenosis secondary to Chlamydia trachomatis: a case report
DOI: 10.17235/reed.2017.4917/2017
Symptomatic retention of the Agile® patency capsule
DOI: 10.17235/reed.2017.4691/2016
The concerns of Spanish patients with inflammatory bowel disease as measured by the RFIPC questionnaire
DOI: 10.17235/reed.2017.4621/2016
Specialist care in the management of inflammatory bowel disease
DOI: 10.17235/reed.2016.4628/2016
Mercaptopurine and inflammatory bowel disease: the other thiopurine
DOI: 10.17235/reed.2016.4546/2016
Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab
DOI: 10.17235/reed.2016.4600/2016
Adalimumab versus infliximab in treating post-operative recurrence of Crohn’s disease: a national cohort study
DOI: 10.17235/reed.2016.4483/2016
Accumulation of mesalazine pills in the medium ileum in a patient with Crohn´s disease
Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn’s disease
DOI: 10.17235/reed.2016.4318/2016
Adnexal localization of Crohn’s disease and recurrent massive ovary cysts
DOI: 10.17235/reed.2016.4301/2016
Community-acquired pneumonia by Legionella pneumophila. Do we need to include new recommendations for inflammatory bowel disease patients under immunomodulators?
DOI: 10.17235/reed.2016.4213/2016
Coloduodenal and enterocutaneous fistula in twins with Crohn´s disease
Comparison of covered and uncovered self-expandable stents in the treatment of malignant biliary obstruction
DOI: 10.17235/reed.2016.4161/2015
Combined endoscopic resolution of iatrogenic stricture in an ureterosigmoidostomy
Predictive factors of small bowel patency in Crohn's disease patients
DOI: 10.17235/reed.2015.3957/2015
Metastatic Crohn’s disease in pediatrics
DOI: 10.17235/reed.2016.3948/2015
Prevention of post-operative recurrence in Crohn´s disease. Are we ready for a treat-to-target strategy?
DOI: 10.17235/reed.2015.3990/2015
Crohn’s disease and Sweet’s syndrome: A debut together
DOI: 10.17235/reed.2015.3842/2015
Impact of endoscopic monitoring in postoperative Crohn’s disease patients already receiving pharmacological prevention of recurrence
DOI: 10.17235/reed.2015.3836/2015
Primary liposarcoma of the sigmoid presenting as colonic intussusception - A case report
DOI: 10.17235/reed.2016.3943/2015
Granulomatous appendicitis as an uncommon cause of abdominal pain. Description of a case
DOI: 10.17235/reed.2015.3763/2015
Ovarian involvement in Crohn´s disease: A rare complication
DOI: 10.17235/reed.2015.3764/2015
Management of refractory esophageal stenosis in the pediatric age
DOI: 10.17235/reed.2016.3671/2015
Acute gastric dilatation in the context of bulimia nervosa
DOI: 10.17235/reed.2015.3673/2015
Obscure gastrointestinal bleeding in a patient with congenital hepatic fibrosis and Crohn´s disease
Download the citation for this article by clicking on one of the following citation managers:
Received: 13/03/2018
Accepted: 25/04/2018
Online First: 31/07/2018
Published: 30/10/2018
Article Online First time: 140 days
Article editing time: 231 days
Submission and tracking
Access to the information published on the website (www.reed.es) of the Sociedad Española de Patología Digestiva (SEPD), Calle Sancho Dávila, 6, 28028 Madrid, CIF: G28486280, telephone: 914021353, e-mail: sepd@sepd.es, implies acceptance of the following conditions of use:
1. The SEPD published its website in order to make it easier for potential visitors to access information related to its services. The information displayed on this website is made available to users accessing the website, both privately and individually, at no additional cost. The commercialization of access rights is expressly prohibited.
2. It is expressly forbidden to copy or reproduce the information published by means of any electronic medium (web pages, databases, web pages or electronic publications) that allows the dissemination of any information published on this website to multiple users without the prior written consent of the SEPD.
3. Accuracy of information: The SEPD endeavors to display accurate and up-to-date information on its website. However, the SEPD is not responsible for the consequences of reading this information.
4. SEPD is not liable for any damages that the user may cause in connection with access to this website or the use of its contents.
5. Notice to users and/or patients: The information included in www.reed.es is for the exclusive use of healthcare professionals and this will be stated in the registration and access alert.
6. Funding: REED, the official scientific body of the EDPS, shares the same sources of funding as the EDPS, as laid down in Article 22, SECTION VII (ECONOMIC AND DOCUMENTARY SYSTEM) of the EDPS's Statutes.
The website http://www.reed.es may host advertising from third parties that may be considered of interest to the user and in no way a source of budgetary funding for the website. Wherever the word 'Advertising' is displayed, it will be highlighted.
However, advertising that infringes Law 29/2006 on guarantees and rational use of medicines and health products will not be accepted. Likewise, there will be no advertising of any kind in those areas of the website where there may be a conflict of interest.
Advertisers have no rights over their editorial content.
7. Access to restricted areas: In relation to access to restricted areas where the user voluntarily completes the registration form, the EDPS will assign the user a password which will be sent to the e-mail address provided by the user, who must make diligent use of the password and keep it secret. Consequently, the user accepts that he/she is responsible for the correct custody and confidentiality of the password/identifier provided by the EDPS. Furthermore, the user shall not provide access to third parties, either temporarily or permanently, or allow access to third parties.
Consequently, the user is solely responsible for all accesses, contents and actions he/she carries out in connection with his/her user ID and access code, with full indemnity for the EDPS.
On this basis, the user is responsible for immediately informing the EDPS of any factors that allow the misuse of the IDs and/or passwords, such as theft, loss or unauthorized access, in order to cancel them immediately. Until such incidents are reported, SEPD will not be liable for any liability that may arise from the misuse of identifiers or passwords by unauthorized third parties.
The user understands and accepts that he/she is accessing a website with content intended exclusively for medical staff and acknowledges that he/she is a healthcare professional.
Notes of interest to members and visitors to the EDPS website: The data and information contained in all content on these websites are only guidance documents for members and are therefore not legally binding.
8. License for public use of the website: is governed by Spanish law, regardless of the country in which the user accesses the website. Any controversy that may arise in the interpretation of these rules of access will be resolved before the Spanish Courts and Tribunals.
Copyright and Creative Commons POR NC ND: The total or partial reproduction of texts and graphics by any means is prohibited without the express written authorization of the EDPS. To insert these texts, images or news items in the publication or dissemination in any medium of any kind accessible to third parties, the express written consent of the EDPS must be obtained.
The private use of the texts, news and data published on this website is strictly for personal purposes.
The General Data Protection Regulation (Regulation (EU) 2016/679) harmonizes Data Protection legislation across the European Union, increasing the protection of individuals and giving them greater control over their personal data.
At the Spanish Society of Digestive Pathology (SEPD), we have always been concerned about the protection of personal data. We have therefore updated our Privacy Policy in order to bring it into line with the new regulations and to inform you of the changes that affect your rights:
Responsible for the processing of your personal data: SOCIEDAD ESPAÑOLA DE PATOLOGÍA DIGESTIVA (SEPD), CIF: G28486280 and registered office at Calle Sancho Dávila 6, 28028 Madrid.
The data collected by the Sociedad Española de Patología Digestiva (SEPD) are obtained in different ways (website, e-mail, electronic forms or on paper) through its activity as a business association and service provider; these data will become part of an information file for which it is responsible.
Purpose of data collection:
Legitimacy of the processing:
Recipients of the data.
Data subjects:
Everyone can know whether or not the EDPS processes their personal data. They have the right to:
SEPD will cease to process the data, except for legitimate reasons, or for the exercise or defense of possible claims.
Origin of the data: SEPD will obtain personal data directly from the data subject through the following communication channels:
Categories of data:
Sending of commercial communications: In accordance with the LSSI, Law 34/2002, and Law 29/2009, of 30 December, if you do not wish to receive any more commercial communications, please send an e-mail with the word BAJA (unsubscribe) to the following address: sepd@sepd.es.
Security measures: SEPD informs that it has adopted all necessary security measures to prevent theft, alteration or unauthorized access to data, taking into account the state of the art, the costs of implementation, the nature, scope, context and purpose of the processing, as well as the variable risks of probability and severity to the rights and freedoms of individuals, such as in cases of outsourced services, request and ensure that the controller implements appropriate technical and organizational measures to ensure an adequate level of security against existing threats, as stated in art. 32 of the Data Protection Regulation.
Exercise of rights:
Everyone has the right to know whether the EDPS processes his or her personal data. He or she also has the right to:
Access their personal data,
Request the rectification of inaccurate data.
Request deletion when, among other reasons, the data are no longer necessary for the purposes for which they were collected.
Object to the processing of your data, on grounds relating to your particular situation, by requesting that they not be processed by the EDPS.
In certain circumstances, request the restriction of the processing of your data, in which case they will only be kept for the exercise or defense of claims.
Withdraw, at any time, the consent given, without this affecting the lawfulness of the processing that we have carried out prior to such withdrawal.
The interested party may exercise their rights at the following address: Sociedad Española de Patología Digestiva (SEPD), c/ Calle Sancho Dávila, 6 28028 Madrid, or by email to the following address: sepd@sepd.es, any controversy that may arise in the interpretation of these access rules will be resolved before the Spanish Courts and Tribunals.
Remember that whenever you exercise any of the rights set out above, you must accompany your request with a copy of your ID card or equivalent document that allows us to verify your identity.
Likewise, if you are not satisfied with how we have dealt with your rights, you may file a complaint with the Spanish Data Protection Agency, through the website www.aepd.es.
The following table describes in detail the cookies present on the website
The user has also been informed of the cookies used by this website by means of the banner that appears on the home screen during the first browsing visit to this website, in which the user can configure them at their own discretion, requesting their consent and management.
A cookie is a small piece of information, usually a few kilobytes to several megabytes in size, which is stored on your terminal when you visit our website. The cookie is used to remember your preferences and other information about your browsing history of our website.
Cookies can be first-party or third-party cookies. This varies depending on whether the cookies are sent to your terminal from a computer or domain managed by us (own cookies), or are sent from a computer or domain not managed by us (third party cookies). They can remain active from a few minutes to several years, or only during the session.
Cookies can have many purposes and sometimes several are grouped together. In addition, there is a group of technical cookies that are necessary for the proper functioning of website, being mandatory to obtain consent for the rest of the cookies with different purposes. Depending on their purpose we can distinguish,
If you wish, you can also manage cookies through your browser. Most browsers are set by default to accept cookies, but you can change the settings to block, delete and manage some or all cookies if you prefer. Please be aware of the possible changes that can occur when deleting or blocking cookies.
Chrome:
https://support.google.com/chrome/answer/95647?hl=es
Explorer:
https://support.microsoft.com/es-es/topic/eliminar-y-administrar-cookies-168dab11-0753-043d-7c16-ede5947fc64d
Edge:
https://support.microsoft.com/es-es/microsoft-edge/eliminar-las-cookies-en-microsoft-edge-63947406-40ac-c3b8-57b9-2a946a29ae09
Safari:
- Ipad, Iphone, Ipod Touch: https://support.apple.com/es-es/HT201265
- Mac: Preferencias, Panel de privacidad
Firefox:
https://support.mozilla.org/es/kb/Borrar%20cookies